RXRA and cancer: The abnormal activation of the PPARγ/RXRα pathway decreases the activity of immune cell infiltration by inhibiting the expression and secretion of inflammatory factors, thereby hampering immunotherapies using immune checkpoint blockade in patients with cancer [30].